The emergence of Coagulase negative Staphylococci (CoNS) as significant pathogen: A study from Wayanad, Kerala

Deepthy B J; Renci T

Volume : VII, Issue : VIII, August - 2018

The emergence of Coagulase negative Staphylococci (CoNS) as significant pathogen: A study from Wayanad, Kerala

Deepthy B J, Renci T

Abstract :

Back ground:Coagulase Negative Staphylococci (CoNS) are the most common commensal flora of human skin and mucous memane. Now it is being increasingly isolated as pure cultures in various samples and difficult to know predict whether it�s a contaminant or actual pathogen.

Aims and objectives:This study was aimed to find out the emergence of Coagulase negative Staphylococci as significant pathogen and to identify out the most common species of CoNS involved in causing infections.

Materials and Methods:This Study was carried out in the Microbiology department of DM WIMS Medical College, Wayanad, Kerala. A total of 5220 samples were studied which included pus, wound, bacteremia, urinary and respiratory tract infections. CoNS were identified and antibiotic sensitivity test was carried out by Kirby baur disk diffusion methods

Results:Out of the 5220 samples, 141 were identified with significant growth of CoNS. Out of this, majority isolates were Staphylococcus epidermidis, 54 isolates which was closely followed by Staphylococcus haemolyticus with an isolation rate of 44, followed by Staphylococcus hominis 13 and 10 each of Staphylococcus warneri, Staphylococcus capitis and Staphylococcus lugdunensis.The antibiotic sensitivity pattern of the isolates revealed 73% resistance to Penicillin, 87% resistance to Ampicillin and 55% resistance to Cefoxitin (MR CoNS). There was less resistance to clindamycin, gentamycin, amikacin.

Conclusions:The study concluded that CoNS can be a pathogen even though they are the most predominant normal flora. ABST reports shows thatdrug resistance CoNS isolates are becoming common. We noted 55% of isolates with cefoxitin resistance. The most susceptible drugs noted was vancomycin and linezolid